Metal gold nanoparticles are of great interest due to their unique physico-chemical properties and their potential to be used as nano-probes in biosensors, drug delivery, and therapeutic applications. Currently, many capping agents are used for metal gold nanoparticles, such as cetyltrimethylammonium bromide (CTAB) and tri-sodium citrate that have been reported to be toxic and hinders biological applications. To address this issue, we report, for the first time, the use of taurine as a stable non-cytotoxic capping agent for synthesizing gold nanoparticles by using an in situ wet-chemical method. This facile method resulted in monodisperse gold nanospheres with a high yield and stability. Monodisperse gold nanospheres with average diameters of 6.9 nm and 46 nm were synthesized at a high yield with controlled morphology. Temperature played a critical role in determining the size of the taurine-capped gold nanoparticles. The subtle changes in the reaction parameters had a tremendous effect on the final size of nanoparticles and their stability. The synthesized nanoparticles were characterized by using optical spectroscopy, a ZetaSizer, a NanoSight, Fourier Transform Infrared (FTIR) spectroscopy, X-ray Diffraction (XRD), X-ray Photon Spectroscopy (XPS) and Electron Microscopy to understand their physico-chemical properties. Taurine was explored as a capping and stabilizing agent for gold nanospheres, which were evaluated for their toxicity responses towards human liver carcinoma cells (HepG2) via MTT assay.

Plasmonic metal nanoparticles are widely used for many applications due to their unique optical and chemical properties. Over the past decade, anisotropic metal nanoparticles have been explored for imaging, sensing, and diagnostic applications. The variations and flexibility of tuning the size and shape of the metal nanoparticles at the nanoscale made them promising candidates for biomedical applications such as therapeutics, diagnostics, and drug delivery. However, safety and risk assessment of the nanomaterials for clinical purposes are yet to be made owing to their cytotoxicity. The toxicity concern is primarily due to the conventional synthesis route that involves surfactants as a structure-directing agent and as a capping agent for nanoparticles. Wet chemical methods employ toxic auxiliary chemicals. However, the approach yields monodispersed nanoparticles, an essential criterion for their intended application and a limitation of the green synthesis of nanoparticles using plant extracts. Several biocompatible counterparts such as polymers, lipids, and chitosan-based nanoparticles have been successfully used in the synthesis of safe nanomaterials, but there were issues regarding reproducibility and yield. Enzymatic degradation was one of the factors responsible for limiting the efficacy. Hence, it is necessary to develop a safer and nontoxic route towards synthesizing biocompatible nanomaterials while retaining morphology, high yield, and monodispersity. In this regard, deep eutectic solvents (DESs) and carrageenan as capping agent for nanoparticles can ensure the safety. Carrageenan has the potential to act as antibacterial and antiviral agent, and adds enhanced stability to the nanoparticles. This leads to a multidimensional approach for utilizing safe nanomaterials for advanced biomedical and clinical applications.

The existing diagnosis and treatment modalities have major limitations related to their precision and capability to understand several stages of disease development. A superior therapeutic system consists of a multifunctional approach in early diagnosis of the disease with a simultaneous progressive cure, using a precise medical approach towards complex treatment. These challenges can be addressed via nanotheranostics and explore suitable approaches to improve health care. Nanotechnology in combination with theranostics as an unconventional platform paved the way for developing novel strategies and modalities leading to diagnosis and therapy for complex disease conditions, ranging from acute to chronic levels. Among the metal nanoparticles, gold nanoparticles are being widely used for theranostics due to their inherent non-toxic nature and plasmonic properties. The unique optical and chemical properties of plasmonic metal nanoparticles along with theranostics have led to a promising era of plausible early detection of disease conditions, and they enable real-time monitoring with enhanced non-invasive or minimally invasive imaging of several ailments. This review aims to highlight the improvement and advancement brought to nanotheranostics by gold nanoparticles in the past decade. The clinical use of the metal nanoparticles in nanotheranostics is explained, along with the future perspectives on addressing the key applications related to diagnostics and therapeutics, respectively. The scope of gold nanoparticles and their realistic potential to design a sophisticated theranostic system is discussed in detail, along with their implications in clinical advancements which are the needs of the hour. The review concluded with the challenges, opportunities, and implications on translational potential of using gold nanoparticles in nanotheranostics.